Kevin N Dalby

List of Publications by Year in Descending Order

141 papers	7,590 citations	34 h-index	85 g-index
154 ext. papers	8,591 ext. citations	5.4 avg, IF	5.22 L-index

#	Paper	IF	Citations
141	The two non-visual arrestins engage ERK2 differently.. *Journal of Molecular Biology*, **2022**, 167465	6.5	0
140	Droplet-based screening of phosphate transfer catalysis reveals how epistasis shapes MAP kinase interactions with substrates.. *Nature Communications*, **2022**, 13, 844	17.4	1
139	Discovery of an Effective Small-Molecule Allosteric Inhibitor of New Delhi Metallo-β-lactamase (NDM).. *ACS Infectious Diseases*, **2022**, 8, 811-824	5.5	1
138	Rapid characterization of spike variants via mammalian cell surface display.. *Molecular Cell*, **2021**, 81, 5099-5111.e8	17.6	4
137	Development of cell-based high throughput luminescence assay for drug discovery in inhibiting OCT4/DNA-PKcs and OCT4-MK2 interactions. *Biotechnology and Bioengineering*, **2021**, 118, 1987-2000	4.9	1
136	A collagen glucosyltransferase drives lung adenocarcinoma progression in mice. *Communications Biology*, **2021**, 4, 482	6.7	3
135	Structural dynamics of the complex of calmodulin with a minimal functional construct of eukaryotic elongation factor 2 kinase and the role of Thr348 autophosphorylation. *Protein Science*, **2021**, 30, 1221-1234	6.3	3
134	Luminescence Energy Transfer-Based Screening and Target Engagement Approaches for Chemical Biology and Drug Discovery. *SLAS Discovery*, **2021**, 26, 984-994	3.4	1
133	Identification of the JNK-Active Triple-Negative Breast Cancer Cluster Associated with an Immunosuppressive Tumor Microenvironment. *Journal of the National Cancer Institute*, **2021**,	9.7	3
132	Development of 2-aminospiro [pyrano[3,2-c]quinoline]-3-carbonitrile derivatives as non-ATP competitive Src kinase inhibitors that suppress breast cancer cell migration and proliferation. *Bioorganic Chemistry*, **2021**, 116, 105344	5.1	3
131	A Robust and Cost-Effective Luminescent-Based High-Throughput Assay for Fructose-1,6-Bisphosphate Aldolase A. *SLAS Discovery*, **2020**, 25, 1038-1046	3.4	1
130	A light-up intercalator displacement assay for detection of triplex DNA stabilizers. *Chemical Communications*, **2020**, 56, 1996-1999	5.8	1
129	JNK Signaling in Stem Cell Self-Renewal and Differentiation. *International Journal of Molecular Sciences*, **2020**, 21,	6.3	23
128	A Toolbox of Structural Biology and Enzyme Kinetics Reveals the Case for ERK Docking Site Inhibition **2020**, 109-139		
127	Differential functions of ERK1 and ERK2 in lung metastasis processes in triple-negative breast cancer. *Scientific Reports*, **2020**, 10, 8537	4.9	13
126	NO-releasing STAT3 inhibitors suppress BRAF-mutant melanoma growth. *European Journal of Medicinal Chemistry*, **2020**, 186, 111885	6.8	19
125	Quantification of ERK Kinase Activity in Biological Samples Using Differential Sensing. *ACS Chemical Biology*, **2020**, 15, 83-92	4.9	6

124	Structural Evaluation of Protein/Metal Complexes via Native Electrospray Ultraviolet Photodissociation Mass Spectrometry. *Journal of the American Society for Mass Spectrometry*, **2020**, 31, 1140-1150	3.5	8
123	Computational and Experimental Studies of Inhibitor Design for Aldolase A. *Journal of Physical Chemistry B*, **2019**, 123, 6034-6041	3.4	8
122	Targeting ERK beyond the boundaries of the kinase active site in melanoma. *Molecular Carcinogenesis*, **2019**, 58, 1551-1570	5	13
121	JNK2 Is Required for the Tumorigenic Properties of Melanoma Cells. *ACS Chemical Biology*, **2019**, 14, 1426-1435	4.9	9
120	Computational insights into the binding of IN17 inhibitors to MELK. *Journal of Molecular Modeling*, **2019**, 25, 151	2	3
119	Solution Structure of the Carboxy-Terminal Tandem Repeat Domain of Eukaryotic Elongation Factor 2 Kinase and Its Role in Substrate Recognition. *Journal of Molecular Biology*, **2019**, 431, 2700-2717	6.5	3
118	Developing Colorimetric and Luminescence-Based High-Throughput Screening Platforms for Monitoring the GTPase Activity of Ferrous Iron Transport Protein B (FeoB). *SLAS Discovery*, **2019**, 24, 597-605	3.4	6
117	A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation. *ACS Chemical Biology*, **2019**, 14, 1183-1194	4.9	12
116	A tunable assay for modulators of genome-destabilizing DNA structures. *Nucleic Acids Research*, **2019**, 47, e73	20.1	5
115	Arrestin-3 interaction with maternal embryonic leucine-zipper kinase. *Cellular Signalling*, **2019**, 63, 109366	4.9	6
114	The role of calcium in the interaction between calmodulin and a minimal functional construct of eukaryotic elongation factor 2 kinase. *Protein Science*, **2019**, 28, 2089-2098	6.3	4
113	Design, synthesis, and DNA interaction studies of furo-imidazo[3.3.3]propellane derivatives: Potential anticancer agents. *Bioorganic Chemistry*, **2019**, 85, 585-599	5.1	8
112	Modulating multi-functional ERK complexes by covalent targeting of a recruitment site in vivo. *Nature Communications*, **2019**, 10, 5232	17.4	9
111	Development of a High-Throughput Lysyl Hydroxylase (LH) Assay and Identification of Small-Molecule Inhibitors against LH2. *SLAS Discovery*, **2019**, 24, 484-491	3.4	11
110	Arrestin-3 scaffolding of the JNK3 cascade suggests a mechanism for signal amplification. *Proceedings of the National Academy of Sciences of the United States of America*, **2019**, 116, 810-815	11.5	24
109	Design, synthesis and biological evaluation of fused naphthofuro[3,2-c] quinoline-6,7,12-triones and pyrano[3,2-c]quinoline-6,7,8,13-tetraones derivatives as ERK inhibitors with efficacy in BRAF-mutant melanoma. *Bioorganic Chemistry*, **2019**, 82, 290-305	5.1	25
108	Development of a cost effective and robust AlphaScreen platform for application. *BioTechniques*, **2018**, 64, 181-183	2.5	3
107	Pro-metastatic collagen lysyl hydroxylase dimer assemblies stabilized by Fe-binding. *Nature Communications*, **2018**, 9, 512	17.4	25

106	A Fluorescence-Based High-Throughput Assay for the Identification of Anticancer Reagents Targeting Fructose-1,6-Bisphosphate Aldolase. *SLAS Discovery*, **2018**, 23, 1-10	3.4	4
105	Elucidating the Phosphate Binding Mode of Phosphate-Binding Protein: The Critical Effect of Buffer Solution. *Journal of Physical Chemistry B*, **2018**, 122, 6371-6376	3.4	14
104	Structural Dynamics of the Activation of Elongation Factor 2 Kinase by Ca-Calmodulin. *Journal of Molecular Biology*, **2018**, 430, 2802-2821	6.5	8
103	A scalable lysyl hydroxylase 2 expression system and luciferase-based enzymatic activity assay. *Archives of Biochemistry and Biophysics*, **2017**, 618, 45-51	4.1	10
102	Tinker-OpenMM: Absolute and relative alchemical free energies using AMOEBA on GPUs. *Journal of Computational Chemistry*, **2017**, 38, 2047-2055	3.5	70
101	Discovery of a potent inhibitor of MELK that inhibits expression of the anti-apoptotic protein Mcl-1 and TNBC cell growth. *Bioorganic and Medicinal Chemistry*, **2017**, 25, 2609-2616	3.4	17
100	c-Jun N-terminal kinase promotes stem cell phenotype in triple-negative breast cancer through upregulation of Notch1 via activation of c-Jun. *Oncogene*, **2017**, 36, 2599-2608	9.2	50
99	Signal Integration at Elongation Factor 2 Kinase: THE ROLES OF CALCIUM, CALMODULIN, AND SER-500 PHOSPHORYLATION. *Journal of Biological Chemistry*, **2017**, 292, 2032-2045	5.4	8
98	Novel quinoline incorporating 1,2,4-triazole/oxime hybrids: Synthesis, molecular docking, anti-inflammatory, COX inhibition, ulceroginicity and histopathological investigations. *Bioorganic Chemistry*, **2017**, 75, 242-259	5.1	33
97	Serotonin Analogues as Inhibitors of Breast Cancer Cell Growth. *ACS Medicinal Chemistry Letters*, **2017**, 8, 1072-1076	4.3	12
96	Local destabilization, rigid body, and fuzzy docking facilitate the phosphorylation of the transcription factor Ets-1 by the mitogen-activated protein kinase ERK2. *Proceedings of the National Academy of Sciences of the United States of America*, **2017**, 114, E6287-E6296	11.5	18
95	MELK: a potential novel therapeutic target for TNBC and other aggressive malignancies. *Expert Opinion on Therapeutic Targets*, **2017**, 21, 849-859	6.4	26
94	Optimization of a Luminescence-Based High-Throughput Screening Assay for Detecting Apyrase Activity. *SLAS Discovery*, **2017**, 22, 94-101	3.4	3
93	A c-Jun N-terminal kinase inhibitor, JNK-IN-8, sensitizes triple negative breast cancer cells to lapatinib. *Oncotarget*, **2017**, 8, 104894-104912	3.3	20
92	193 nm Ultraviolet Photodissociation Mass Spectrometry for Phosphopeptide Characterization in the Positive and Negative Ion Modes. *Journal of Proteome Research*, **2016**, 15, 2739-48	5.6	34
91	Peptide mini-scaffold facilitates JNK3 activation in cells. *Scientific Reports*, **2016**, 6, 21025	4.9	42
90	Definition of a Novel Feed-Forward Mechanism for Glycolysis-HIF1 Signaling in Hypoxic Tumors Highlights Aldolase A as a Therapeutic Target. *Cancer Research*, **2016**, 76, 4259-4269	10.1	43
89	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). *Autophagy*, **2016**, 12, 1-222	10.2	3838

88	Application of Eukaryotic Elongation Factor-2 Kinase (eEF-2K) for Cancer Therapy: Expression, Purification, and High-Throughput Inhibitor Screening. *Methods in Molecular Biology*, **2016**, 1360, 19-33	1.4	2
87	Longitudinal tracking of subpopulation dynamics and molecular changes during LNCaP cell castration and identification of inhibitors that could target the PSA-/lo castration-resistant cells. *Oncotarget*, **2016**, 7, 14220-40	3.3	12
86	Structure of the C-Terminal Helical Repeat Domain of Eukaryotic Elongation Factor 2 Kinase. *Biochemistry*, **2016**, 55, 5377-86	3.2	4
85	Structural Basis for the Recognition of Eukaryotic Elongation Factor 2 Kinase by Calmodulin. *Structure*, **2016**, 24, 1441-51	5.2	15
84	Arrestin-3-Dependent Activation of c-Jun N-Terminal Kinases (JNKs). *Current Protocols in Pharmacology*, **2015**, 68, 2.12.1-2.12.26	4.1	11
83	Mechanistic Studies on Covalent Assemblies of Metal-Mediated Hemi-Aminal Ethers. *Chemical Science*, **2015**, 6, 158-164	9.4	24
82	MEK Inhibitor Selumetinib (AZD6244; ARRY-142886) Prevents Lung Metastasis in a Triple-Negative Breast Cancer Xenograft Model. *Molecular Cancer Therapeutics*, **2015**, 14, 2773-81	6.1	51
81	Quantification of a Pharmacodynamic ERK End Point in Melanoma Cell Lysates: Toward Personalized Precision Medicine. *ACS Medicinal Chemistry Letters*, **2015**, 6, 47-52	4.3	11
80	Structural and Dynamic Features of F-recruitment Site Driven Substrate Phosphorylation by ERK2. *Scientific Reports*, **2015**, 5, 11127	4.9	13
79	Using docking and alchemical free energy approach to determine the binding mechanism of eEF2K inhibitors and prioritizing the compound synthesis. *Frontiers in Molecular Biosciences*, **2015**, 2, 9	5.6	15
78	Overexpression of GRK6 rescues L-DOPA-induced signaling abnormalities in the dopamine-depleted striatum of hemiparkinsonian rats. *Experimental Neurology*, **2015**, 266, 42-54	5.7	16
77	Targeting the transient receptor potential-melastatin-like 7 (Trpm7) kinase domain with the first inhibitor, inhibited breast cancer cell migration, invasion and tumor metastasis.. *FASEB Journal*, **2015**, 29, 1021.9	0.9	
76	Reversible covalent inhibition of eEF-2K by carbonitriles. *ChemBioChem*, **2014**, 15, 2435-42	3.8	20
75	Synthesis and biological evaluation of pyrido[2,3-d]pyrimidine-2,4-dione derivatives as eEF-2K inhibitors. *Bioorganic and Medicinal Chemistry*, **2014**, 22, 4910-6	3.4	44
74	Identification and validation of novel PERK inhibitors. *Journal of Chemical Information and Modeling*, **2014**, 54, 1467-75	6.1	10
73	Propyphenazone-based analogues as prodrugs and selective cyclooxygenase-2 inhibitors. *ACS Medicinal Chemistry Letters*, **2014**, 5, 983-8	4.3	7
72	Modeling organochlorine compounds and the Ehole effect using a polarizable multipole force field. *Journal of Physical Chemistry B*, **2014**, 118, 6456-65	3.4	65
71	Differential sensing of MAP kinases using SOX-peptides. *Angewandte Chemie - International Edition*, **2014**, 53, 14064-8	16.4	33

70	Differential Sensing of MAP Kinases Using SOX-Peptides. *Angewandte Chemie*, **2014**, 126, 14288-14292	3.6	5
69	The molecular mechanism of eukaryotic elongation factor 2 kinase activation. *Journal of Biological Chemistry*, **2014**, 289, 23901-16	5.4	24
68	High-throughput screens for eEF-2 kinase. *Journal of Biomolecular Screening*, **2014**, 19, 445-52		19
67	In-situ generation of differential sensors that fingerprint kinases and the cellular response to their expression. *Journal of the American Chemical Society*, **2013**, 135, 14814-20	16.4	54
66	Construction of human activity-based phosphorylation networks. *Molecular Systems Biology*, **2013**, 9, 655	12.2	134
65	A fluorescence-based assay for p38 recruitment site binders: identification of rooperol as a novel p38 kinase inhibitor. *ChemBioChem*, **2013**, 14, 66-71	3.8	12
64	Elucidating binding modes of zuonin A enantiomers to JNK1 via in silico methods. *Journal of Molecular Graphics and Modelling*, **2013**, 45, 38-44	2.8	2
63	High-throughput database search and large-scale negative polarity liquid chromatography-tandem mass spectrometry with ultraviolet photodissociation for complex proteomic samples. *Molecular and Cellular Proteomics*, **2013**, 12, 2604-14	7.6	28
62	Arrestin-3 binds c-Jun N-terminal kinase 1 (JNK1) and JNK2 and facilitates the activation of these ubiquitous JNK isoforms in cells via scaffolding. *Journal of Biological Chemistry*, **2013**, 288, 37332-42	5.4	51
61	JNK3 enzyme binding to arrestin-3 differentially affects the recruitment of upstream mitogen-activated protein (MAP) kinase kinases. *Journal of Biological Chemistry*, **2013**, 288, 28535-47	5.4	41
60	BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signaling. *ELife*, **2013**, 2, e00969	8.9	51
59	Evidence of the Regulation of JNK2 through Oligomerization. *FASEB Journal*, **2013**, 27, 789.22	0.9	
58	JNK3 binding to arrestin-3 differentially affects recruitment of upstream MAP kinase kinases. *FASEB Journal*, **2013**, 27, 1042.4	0.9	
57	Manipulating JNK signaling with (--)-zuonin A. *ACS Chemical Biology*, **2012**, 7, 1873-83	4.9	19
56	Calcium/calmodulin stimulates the autophosphorylation of elongation factor 2 kinase on Thr-348 and Ser-500 to regulate its activity and calcium dependence. *Biochemistry*, **2012**, 51, 2232-45	3.2	44
55	From in Silico Discovery to intra-Cellular Activity: Targeting JNK-Protein Interactions with Small Molecules. *ACS Medicinal Chemistry Letters*, **2012**, 3, 721-725	4.3	24
54	Docking interactions of hematopoietic tyrosine phosphatase with MAP kinases ERK2 and p38 *Biochemistry*, **2012**, 51, 8047-9	3.2	17
53	Induction of Autophagy by Polyphenolic Compounds in Cancer: A Novel Strategy to induce cell death and to Treat Cancer **2012**, 237-261		1

52	Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. *PLoS ONE*, **2012**, 7, e41171	3.7	84
51	Investigating the kinetic mechanism of inhibition of elongation factor 2 kinase by NH125: evidence of a common in vitro artifact. *Biochemistry*, **2012**, 51, 2100-12	3.2	44
50	Charge-site-dependent dissociation of hydrogen-rich radical peptide cations upon vacuum UV photoexcitation. *Chemistry - A European Journal*, **2012**, 18, 5374-83	4.8	19
49	Computational insights for the discovery of non-ATP competitive inhibitors of MAP kinases. *Current Pharmaceutical Design*, **2012**, 18, 1173-85	3.3	18
48	Assignment of backbone resonances in a eukaryotic protein kinase - ERK2 as a representative example. *Methods in Molecular Biology*, **2012**, 831, 359-68	1.4	9
47	Understanding the specificity of a docking interaction between JNK1 and the scaffolding protein JIP1. *Journal of Physical Chemistry B*, **2011**, 115, 1491-502	3.4	29
46	Purification and characterization of tagless recombinant human elongation factor 2 kinase (eEF-2K) expressed in Escherichia coli. *Protein Expression and Purification*, **2011**, 79, 237-44	2	23
45	The effect of arrestin conformation on the recruitment of c-Raf1, MEK1, and ERK1/2 activation. *PLoS ONE*, **2011**, 6, e28723	3.7	69
44	Virtual screening using molecular simulations. *Proteins: Structure, Function and Bioinformatics*, **2011**, 79, 1940-51	4.2	128
43	193-nm photodissociation of singly and multiply charged peptide anions for acidic proteome characterization. *Proteomics*, **2011**, 11, 1329-34	4.8	64
42	Examining docking interactions on ERK2 with modular peptide substrates. *Biochemistry*, **2011**, 50, 9500-10	3.2	30
41	Nonvisual arrestins function as simple scaffolds assembling the MKK4-JNK3 signaling complex. *Biochemistry*, **2011**, 50, 10520-9	3.2	54
40	Development of JNK2-selective peptide inhibitors that inhibit breast cancer cell migration. *ACS Chemical Biology*, **2011**, 6, 658-66	4.9	38
39	Activated ERK2 is a monomer in vitro with or without divalent cations and when complexed to the cytoplasmic scaffold PEA-15. *Biochemistry*, **2011**, 50, 4568-78	3.2	34
38	Solution NMR insights into docking interactions involving inactive ERK2. *Biochemistry*, **2011**, 50, 3660-72	3.2	32
37	A model of a MAPK substrate complex in an active conformation: a computational and experimental approach. *PLoS ONE*, **2011**, 6, e18594	3.7	17
36	Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. *Autophagy*, **2010**, 6, 322-9	10.2	361
35	Fluorescent peptide assays for protein kinases. *Current Protocols in Molecular Biology*, **2010**, Chapter 18, Unit 18.17	2.9	5

34	Phosphorylation of the transcription factor Ets-1 by ERK2: rapid dissociation of ADP and phospho-Ets-1. *Biochemistry*, **2010**, 49, 3619-30	3.2	21
33	Conformational preference of ChaK1 binding peptides: a molecular dynamics study. *PMC Biophysics* , **2010**, 3, 2		2
32	Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles. *Bioorganic and Medicinal Chemistry Letters*, **2009**, 19, 6293-7	2.9	19
31	Haloperidol and clozapine differentially affect the expression of arrestins, receptor kinases, and extracellular signal-regulated kinase activation. *Journal of Pharmacology and Experimental Therapeutics*, **2008**, 325, 276-83	4.7	46
30	Substrate discrimination among mitogen-activated protein kinases through distinct docking sequence motifs. *Journal of Biological Chemistry*, **2008**, 283, 19511-20	5.4	115
29	Expanding the repertoire of an ERK2 recruitment site: cysteine footprinting identifies the D-recruitment site as a mediator of Ets-1 binding. *Biochemistry*, **2007**, 46, 9174-86	3.2	31
28	The anti-apoptotic protein PEA-15 is a tight binding inhibitor of ERK1 and ERK2, which blocks docking interactions at the D-recruitment site. *Biochemistry*, **2007**, 46, 9187-98	3.2	46
27	Dopamine depletion and subsequent treatment with L-DOPA, but not the long-lived dopamine agonist pergolide, enhances activity of the Akt pathway in the rat striatum. *Journal of Neurochemistry*, **2007**, 102, 699-711	6	64
26	The expression and purification of the N-terminal activation domain of the transcription factor c-Myc: a model substrate for exploring ERK2 docking interactions. *Protein Expression and Purification*, **2007**, 53, 80-6	2	3
25	Regulation of protein phosphorylation within the MKK1-ERK2 complex by MP1 and the MP1*P14 heterodimer. *Archives of Biochemistry and Biophysics*, **2007**, 460, 85-91	4.1	5
24	Properties and regulation of a transiently assembled ERK2.Ets-1 signaling complex. *Biochemistry*, **2006**, 45, 13719-33	3.2	42
23	11 Reaction mechanisms. *Annual Reports on the Progress of Chemistry Section B*, **2005**, 101, 264		
22	Proximity-induced catalysis by the protein kinase ERK2. *Journal of the American Chemical Society*, **2005**, 127, 10494-5	16.4	41
21	Quantifying ERK2-protein interactions by fluorescence anisotropy: PEA-15 inhibits ERK2 by blocking the binding of DEJL domains. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2005**, 1754, 316-23	4	23
20	Following in vitro activation of mitogen-activated protein kinases by mass spectrometry and tryptic peptide analysis: purifying fully activated p38 mitogen-activated protein kinase alpha. *Analytical Biochemistry*, **2005**, 336, 1-10	3.1	9
19	Kinetic mechanism for p38 MAP kinase alpha. A partial rapid-equilibrium random-order ternary-complex mechanism for the phosphorylation of a protein substrate. *FEBS Journal*, **2005**, 272, 4631-45	5.7	18
18	Phage display identifies novel peptides that bind extracellular-regulated protein kinase 2 to compete with transcription factor binding. *Journal of Physical Organic Chemistry*, **2004**, 17, 461-471	2.1	
17	A kinetic approach towards understanding substrate interactions and the catalytic mechanism of the serine/threonine protein kinase ERK2: identifying a potential regulatory role for divalent magnesium. *Biochimica Et Biophysica Acta - Proteins and Proteomics*, **2004**, 1697, 81-7	4	11

16	12 Reaction mechanisms. *Annual Reports on the Progress of Chemistry Section B*, **2004**, 100, 311-333		0
15	Conserved elements of the cytochrome P-450 superfamily found in monoamine oxidase B. *NeuroToxicology*, **2004**, 25, 73-8	4.4	
14	Physiological concentrations of divalent magnesium ion activate the serine/threonine specific protein kinase ERK2. *Biochemistry*, **2003**, 42, 2960-70	3.2	43
13	Two rate-limiting steps in the kinetic mechanism of the serine/threonine specific protein kinase ERK2: a case of fast phosphorylation followed by fast product release. *Biochemistry*, **2003**, 42, 12273-86	3.2	37
12	10 Reaction mechanisms. *Annual Reports on the Progress of Chemistry Section B*, **2003**, 99, 351		0
11	Transient protein-protein interactions and a random-ordered kinetic mechanism for the phosphorylation of a transcription factor by extracellular-regulated protein kinase 2. *Journal of Biological Chemistry*, **2002**, 277, 12532-40	5.4	31
10	Toward a stable hydroxyphosphorane. *Organic Letters*, **2002**, 4, 201-3	6.2	12
9	6 Reaction mechanisms. *Annual Reports on the Progress of Chemistry Section B*, **2002**, 98, 253-291		1
8	The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogen-activated protein (MAP) kinase alpha. Implications for signal/response profiles of MAP kinase pathways. *Journal of Biological Chemistry*, **2001**, 276, 5676-84	5.4	61
7	Purification of a model substrate for transcription factor phosphorylation by ERK2. *Protein Expression and Purification*, **2001**, 23, 191-7	2	20
6	Mechanism of catalysis of the hydrolysis of a formamidinium compound. *Perkin Transactions II RSC*, **2001**, 1961-1967		
5	Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. *Journal of Biological Chemistry*, **1998**, 273, 1496-505	5.4	292
4	Lifetimes of Imidinium Ions in Aqueous Solution. *Journal of the American Chemical Society*, **1997**, 119, 7271-7280	16.4	7
3	Comparison of the specificities of p70 S6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 S6 kinase: the N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide phosphorylation. *FEBS Letters*, **1995**, 375, 289-93	3.8	107
2	Models for nuclease catalysis: mechanisms for general acid catalysis of the rapid intramolecular displacement of methoxide from a phosphate diester. *Journal of the Chemical Society Perkin Transactions II*, **1993**, 1269		21
1	Electrostatic catalysis of the hydrolysis of a phosphate diester in water. *Journal of the Chemical Society Chemical Communications*, **1992**, 1770		3